scholarly journals Locomotor Improvement after Spinal Cord Injury by Multiple Injections of Bone Marrow Mononuclear Cells without Local Inflammatory Modulation

2015 ◽  
Vol 5 (1_suppl) ◽  
pp. s-0035-1554323-s-0035-1554323
Author(s):  
Francine Bonatto ◽  
Asdrubal Falavigna ◽  
Jaderson DaCosta
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Mononuclear Cells ◽  
Bone Marrow Mononuclear Cells ◽  
Multiple Injections ◽  
Cord Injury ◽  
Inflammatory Modulation

scholarly journals Two intrathecal transplants of bone marrow mononuclear cells produce motor improvement in an acute and severe model of spinal cord injury

2013 ◽  
Vol 12 (4) ◽  
pp. 274-277 ◽  
Author(s):  
Elisa Lettnin Kaminski ◽  
Asdrubal Falavigna ◽  
Gianina Terribele Venturin ◽  
Daniel Marinowic ◽  
Pamela Brambilla Bagatini ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Motor Function ◽  
Histological Analysis ◽  
Mononuclear Cells ◽  
Pcr Analysis ◽  
Bone Marrow Mononuclear Cells ◽  
Injury Site ◽  
Cord Injury

OBJECTIVE: We studied transplants of bone marrow mononuclear cells (BMMC) by lumbar puncture (LP) in a severe model of spinal cord injury (SCI) using clip compression. METHODS: BMMCs or saline solution were transplanted by LP 48 hours and 9 days post injury. Motor function was evaluated by BBB scale, histological analysis by Nissl technique and the verification of cell migration by PCR analysis. RESULTS: The BBB had significantly improved in rats treated with BMMCs by LP compared with controls (p<0.001). The histological analysis did not showed difference in the lesional area between the groups. The PCR analysis was able to found BMMCs in the injury site. CONCLUSIONS: two BMMC transplants by LP improved motor function in a severe model of SCI and BMMC was found in the injury site.

Effects of Multiple Injection of Bone Marrow Mononuclear Cells on Spinal Cord Injury of Rats

2017 ◽  
Vol 34 (21) ◽  
pp. 3003-3011 ◽  
Author(s):  
Kenji Kanekiyo ◽  
Norihiko Nakano ◽  
Tamami Homma ◽  
Yoshihiro Yamada ◽  
Masahiro Tamachi ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Mononuclear Cells ◽  
Bone Marrow Mononuclear Cells ◽  
Multiple Injection ◽  
Cord Injury

scholarly journals NeuroRegen Scaffolds Combined with Autologous Bone Marrow Mononuclear Cells for the Repair of Acute Complete Spinal Cord Injury: A 3-Year Clinical Study

2020 ◽  
Vol 29 ◽  
pp. 096368972095063
Author(s):  
Wugui Chen ◽  
Ying Zhang ◽  
Sizhen Yang ◽  
Jing Sun ◽  
Hao Qiu ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Stem Cell ◽  
Mononuclear Cells ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cells ◽  
Cord Injury ◽  
Autologous Bone

Spinal cord injury (SCI) remains among the most challenging pathologies worldwide and has limited therapeutic possibilities and a very bleak prognosis. Biomaterials and stem cell transplantation are promising treatments for functional recovery in SCI. Seven patients with acute complete SCI diagnosed by a combination of methods were included in the study, and different lengths (2.0–6.0 cm) of necrotic spinal cord tissue were surgically cleaned under intraoperative neurophysiological monitoring. Subsequently, NeuroRegen scaffolds loaded with autologous bone marrow mononuclear cells (BMMCs) were implanted into the cleaned site. All patients participated in 6 months of rehabilitation and at least 3 years of clinical follow-up. No adverse symptoms associated with stem cell or functional scaffold implantation were observed during the 3-year follow-up period. Additionally, partial shallow sensory and autonomic nervous functional improvements were observed in some patients, but no motor function recovery was observed. Magnetic resonance imaging suggested that NeuroRegen scaffold implantation supported injured spinal cord continuity after treatment. These findings indicate that implantation of NeuroRegen scaffolds combined with stem cells may serve as a safe and promising clinical treatment for patients with acute complete SCI. However, determining the therapeutic effects and exact application methods still requires further study.

Neuroprotective Effect of Bone Marrow–Derived Mononuclear Cells Promoting Functional Recovery from Spinal Cord Injury

2007 ◽  
Vol 24 (6) ◽  
pp. 1026-1036 ◽  
Author(s):  
Tomoyuki Yoshihara ◽  
Masayoshi Ohta ◽  
Yutaka Itokazu ◽  
Naoya Matsumoto ◽  
Mari Dezawa ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Functional Recovery ◽  
Mononuclear Cells ◽  
Neuroprotective Effect ◽  
Cord Injury

scholarly journals Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A Comparative Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Vidyasagar Devaprasad Dedeepiya ◽  
Yegneswara Yellury Rao ◽  
Gosalakkal A. Jayakrishnan ◽  
Jutty K. B. C. Parthiban ◽  
Subramani Baskar ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
General Population ◽  
Mononuclear Cells ◽  
Age Groups ◽  
Reproductive Age ◽  
Cd34 Cells ◽  
Cord Injury ◽  
And Gender

Introduction. Recent evidence of safety and efficacy of Bone Marrow Mononuclear Cells (BMMNC) in spinal cord injury makes the Bone Marrow (BM) CD34+ percentage and the BMMNC count gain significance. The indices of BM that change with body mass index and aging in general population have been reported but seldom in Spinal Cord Injury (SCI) victims, whose parameters of relevance differ from general population. Herein, we report the indices of BMMNC in SCI victims. Materials and Methods. BMMNCs of 332 SCI patients were isolated under GMP protocols. Cell count by Trypan blue method and CD34+ cells by flow cytometry were documented and analysed across ages and gender. Results. The average BMMNC per ml in the age groups 0–20, 21–40, 41–60, and 61–80 years were 4.71, 4.03, 3.67, and 3.02 million and the CD34+ were 1.05%, 1.04%, 0.94%, and 0.93% respectively. The decline in CD34+ was sharp between 20–40 and 40–60 age groups. Females of reproductive age group had lesser CD34+. Conclusion. The BMMNC and CD34+ percentages decline with aging in SCI victims. Their lower values in females during reproductive age should be analysed for relevance to hormonal influence. This study offers reference values of BMMNC and CD34+ of SCI victims for successful clinical application.

scholarly journals Comparison among bone marrow mesenchymal stem and mononuclear cells to promote functional recovery after spinal cord injury in rabbits

2017 ◽  
Vol 32 (12) ◽  
pp. 1026-1035
Author(s):  
Antônio Filipe Braga Fonseca ◽  
Jussara Peters Scheffer ◽  
Arthur Giraldi-Guimarães ◽  
Bárbara Paula Coelho ◽  
Raphael Mansur Medina ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Functional Recovery ◽  
Mononuclear Cells ◽  
Cord Injury

Bone marrow mesenchymal stem cells-derived exosomes reduce apoptosis and inflammatory response during spinal cord injury by inhibiting the TLR4/MyD88/NF-κB signaling pathway

2021 ◽  
pp. 096032712110033
Author(s):  
Liying Fan ◽  
Jun Dong ◽  
Xijing He ◽  
Chun Zhang ◽  
Ting Zhang
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Mesenchymal Stem Cells ◽  
Motor Function ◽  
Inflammatory Factors ◽  
Cord Injury ◽  
Marrow Mesenchymal Stem Cells ◽  
Apoptosis And Inflammation

Spinal cord injury (SCI) is one of the most common destructive injuries, which may lead to permanent neurological dysfunction. Currently, transplantation of bone marrow mesenchymal stem cells (BMSCs) in experimental models of SCI shows promise as effective therapies. BMSCs secrete various factors that can regulate the microenvironment, which is called paracrine effect. Among these paracrine substances, exosomes are considered to be the most valuable therapeutic factors. Our study found that BMSCs-derived exosomes therapy attenuated cell apoptosis and inflammation response in the injured spinal cord tissues. In in vitro studies, BMSCs-derived exosomes significantly inhibited lipopolysaccharide (LPS)-induced PC12 cell apoptosis, reduced the secretion of pro-inflammatory factors including tumor necrosis factor (TNF)-α and IL (interleukin)-1β and promoted the secretion of anti-inflammatory factors including IL-10 and IL-4. Moreover, we found that LPS-induced protein expression of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88) and nuclear transcription factor-κB (NF-κB) was significantly downregulated after treatment with BMSCs-derived exosomes. In in vivo studies, we found that hindlimb motor function was significantly improved in SCI rats with systemic administration of BMSCs-derived exosomes. We also observed that the expression of pro-apoptotic proteins and pro-inflammatory factors was significantly decreased, while the expression of anti-apoptotic proteins and anti-inflammatory factors were upregulated in SCI rats after exosome treatment. In conclusion, BMSCs-derived exosomes can inhibit apoptosis and inflammation response induced by injury and promote motor function recovery by inhibiting the TLR4/MyD88/NF-κB signaling pathway, which suggests that BMSCs-derived exosomes are expected to become a new therapeutic strategy for SCI.

Sign in / Sign up

Export Citation Format

Share Document